Was VE-821 Actually Worth The Pounds?

5?��?103/��L on three consecutive days. We calculated the cumulative incidence (CI) of IFD, using time to first IFD, defined as the date of diagnosis of IFD minus the first date in the cohort. this website The date of the diagnosis of IFD was defined as the date of the first clinical documentation of infection; if the diagnosis was obtained post mortem, the date of death was recorded as the date of diagnosis of IFD. For the calculation of the CI, we considered relapse of the underlying disease and death from causes not related to IFD as competing events. The Grey test was used for comparison between curves. One-year survival was calculated using the Kaplan�CMeier method and the curves were compared with the log rank test. We used the cmprisk package (R, version 2.14.1) to calculate CI, and the SPSS package (SPSS, Inc., Chicago, IL version 15.0) for the other analyses. During the study period a total of 954 disease episodes were registered in the Azastene database. Eleven disease episodes in the AML/MDS cohort and six in the HCT cohort were excluded because of incomplete data. We therefore analysed 937 disease episodes: 237 induction remission courses of AML/MDS (in 202 patients) and 700 HCTs (in 673 patients). The median age of the 875 patients was 37?years (0�C82?years), and 56% were male. As shown in Table?1, the most frequent underlying disease among allogeneic HCT recipients was AML, followed by acute lymphoid leukaemia, whereas multiple myeloma accounted for 47.5% of autologous HCT. Most allogeneic HCTs were myeloablative (80.4%), from a matched related donor (71.7%), with the bone marrow as the stem cell source (56.1%). During the study period a total of 108 episodes of IFD were diagnosed, 66 of which (61%) were proven or probable. Table?2 shows the classification and aetiology of the 66 proven or probable IFD. Invasive fusariosis was the leading IFD (23 episodes, including Pictilisib three mixed infections), followed by aspergillosis (20 episodes, including one mixed infection), invasive candidiasis (11 episodes, including one mixed infection) and hyalohyphomycosis (eight episodes). Only three cases of mucormycosis were diagnosed, all in allogeneic HCT recipients. The 1-year CI of all IFD in the entire cohort was 8.7%, and varied from 4.7% to 24.2% in the eight centres. The CI of the different aetiologies of IFD varied among the eight centres. Two centres did not report any case of invasive aspergillosis (IA), whereas in two the CI was >7%. Fusariosis was reported in all but two centres, with five centres reporting CI >3%. Candidiasis was reported in four centres and mucormycosis in three. The 1-year CI of all IFD differed according to patient��s age: 6.5% in patients 60?years old (p?0.03). As shown in Fig.?1, the 1-year CI of all IFD was 18.7% in AML/MDS and 7.2% in HCT (11.3% in allogeneic HCT and 1.9% in autologous HCT, p?